Mr. Hurst is an entrepreneur that has driven R&D, go-to-market, and reimbursement strategies for biopharmaceutical, genomic, and molecular diagnostic products. He has played an active role in the molecular testing industry focusing on oncology, pharmacogenomics (PGx), and clinical services. Mr. Hurst has created presentations, product roadmaps, data-driven pricing, and reimbursement strategies by leading product development core teams and cross-functional teams for mission-critical projects that generated increased revenue growth rate for several companies. By forging professional relationships with key-opinion leaders (KOLs), business partners, and consultants, he has launched several novel clinical genetic tests using multiple sequencing technology platforms. He has market experience in product development and commercialization of novel intellectual property (IP); including bench to bedside products for licensed IP from institutions such as Vanderbilt and John Hopkins. With a target goal of creating a global scientific presence, Mr. Hurst has developed targeted messaging, product guides, market brochures, webinars, and videos for education and diverse customer segments. Through KOL and customer engagement at provider sites, company exhibitions, surveys, and workshops, he has captured customer feedback and sales to drive product adoption, clinical services, and custom laboratory software development. To achieve the fastest path to market for novel diagnostic products, Mr. Hurst played a critical role in leading multiple validation projects through CMS implementation guidelines for laboratory-developed tests (LDTs), including actionable report generation by working with KOLs and Laboratory Directors. Mr. Hurst has a proven ability to drive revenue, create corporate growth, and return value to his investors and clients.